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Limb-bud and heart (LBH) is a novel key transcriptional regulator of vertebrate development. However, the
molecular mechanisms upstream of LBH and its role in adult development are unknown. Here we show that
in epithelial development, LBH expression is tightly controlled by Wnt signaling. LBH is transcriptionally
induced by the canonical Wnt pathway, as evident by the presence of conserved functional T-cell factor
(TCF)/lymphoid enhancer-binding factor (LEF) binding sites in the LBH locus and rapid -catenin-dependent
upregulation of endogenous LBH by Wnt3a. In contrast, LBH induction by Wnt/-catenin signaling is inhibited
by Wnt7a, which in limb development signals through a noncanonical pathway involving Lmx1b. Furthermore,
we show that LBH is aberrantly overexpressed in mammary tumors of mouse mammary tumor virus (MMTV)-
Wnt1-transgenic mice and in aggressive basal subtype human breast cancers that display Wnt/-catenin
hyperactivation. Deregulation of LBH in human basal breast cancer appears to be Wnt/-catenin dependent,
as DKK1 and Wnt7a inhibit LBH expression in breast tumor cells. Overexpression studies indicate that LBH
suppresses mammary epithelial cell differentiation, an effect that could contribute to Wnt-induced tumorigen-
esis. Taken together, our findings link LBH for the first time to the Wnt signaling pathway in both development
and cancer and highlight LBH as a potential new marker for therapeutically challenging basal-like breast
cancers.
Increasing evidence suggests that embryonic development
and tumorigenesis share some of the same molecular mecha-
nisms. In particular, aberrant reactivation of latent develop-
mental signaling pathways and transcription factors in tumor
cells has been associated with and shown to play causal roles in
advanced-stage, invasive cancers (5, 6, 80).
Limb-bud and heart (LBH) is a highly conserved, novel
tissue-specific transcription cofactor in vertebrates with impor-
tant roles in embryonic development (7, 8, 19). We have pre-
viously identified Lbh as a novel mouse gene with unique
spatiotemporal expression during early embryogenesis that re-
flects pattern formation in the developing limb buds and heart
(8). Lbh encodes a small acidic protein (molecular mass, 12.3
kDa) that contains a conserved putative nuclear localization
signal and a glutamate-rich putative transcriptional activation
domain but lacks a DNA binding domain (DBD) (8). In mam-
malian reporter assays, LBH has both transcriptional activator
and corepressor functions (7, 8). Recent biophysical analysis
has revealed a high degree of structural disorder in LBH,
suggesting that conformational plasticity may play a signif-
icant role in modulating LBH-dependent transcriptional
processes (2).
Aberrant gain of LBH function is associated with partial
trisomy 2p syndrome (7), a rare human autosomal disorder
that is characterized by multiple congenital anomalies, includ-
ing cardiovascular, skeletal, and postaxial limb defects (46).
Partial trisomy 2p syndrome patients harbor a triplication of
chromosomal region 2p23, where LBH maps, indicating that
increased LBH gene dosage is pathological in humans (7).
Transgenic misexpression of Lbh during embryonic heart de-
velopment in mice phenocopies congenital heart disease ob-
served in these patients (7) and indicates that Lbh functions to
attenuate cardiac chamber differentiation through corepres-
sion of key cardiac transcription factors NKX2.5 and TBX5
(7). Interestingly, gain of function of LBH during mouse heart
development also causes various growth defects, such as ven-
tricular hyperplasia and increased cardiac valve formation, as
well as the abnormally sustained self-renewal of cardiomyo-
cytes after birth, suggesting that LBH has promitogenic activity
(7). Consistent with these findings, retroviral overexpression of
Lbh in chicken embryonic limbs leads to increased cell prolif-
eration of immature chondrocytes and markedly delays bone
differentiation (19). However, the regulatory pathways acting
upstream of LBH and its role in adult development have re-
mained obscure.
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Wnt signaling plays a fundamental role in embryonic devel-
opment by regulating pattern formation, cell proliferation, dif-
ferentiation, and migration (44). Wnt ligands are secreted
lipid-modified glycoproteins that act as morphogens and elicit
different cell behaviors depending on whether receptor inter-
action activates a canonical -catenin-dependent transduction
pathway or other -catenin-independent noncanonical path-
ways (39, 73). In adults, canonical Wnt signaling promotes the
self-renewal and maintenance of stem cells required for nor-
mal tissue homeostasis (52), a function that becomes onco-
genic when this pathway is deregulated (18). Activation of
canonical Wnt signaling leads to the stabilization of cyto-
plasmic -catenin and its subsequent translocation into the
nucleus, where it forms a heteromeric complex with DNA-
binding proteins of the T-cell factor (TCF)/lymphoid en-
hancer-binding factor (LEF) family to activate target gene
transcription (18). In the absence of Wnt, TCF/LEF factors
are bound to target gene promoters but act as transcrip-
tional repressors by forming a complex with Groucho/Grg/
TLE corepressors (18). The amplitude of canonical Wnt
signaling is autoregulated via multiple positive and negative
feedback mechanisms that include TCF/LEF factors them-
selves and the secreted antagonist Dickkopf 1 (DKK1), re-
spectively (13, 18, 26, 51). In addition, Wnt ligands can activate
multiple noncanonical signaling pathways, including the planar
cell polarity (PCP) and Wnt/Ca2 pathways and, in the case of
Wnt7a in limb development, a pathway involving the homeodo-
main transcription factor Lmx1b (37, 62).
Genetic studies of mice first indicated that canonical Wnt
signaling is oncogenic and implicated in breast cancer. Aber-
rant activation of Wnt1 through proviral integration of the
mouse mammary tumor virus (MMTV) causes aggressive
mammary tumors in mice (53, 71). Similarly, transgenic over-
expression of stabilized -catenin in mouse mammary glands
results in formation of invasive mammary adenocarcinomas
(33, 69). Abnormal activation of the canonical Wnt pathway is
also associated with human breast cancer (41) and is most
common in a highly aggressive subtype of breast cancers
known as basal carcinomas (22, 28, 38, 64). This tumor subtype
accounts for 15 to 20% of breast cancers and is characterized
by early onset and a highly invasive, poorly differentiated (ker-
atin 5/6-positive) tumor phenotype. Basal-like breast cancers
have a poor clinical outcome and represent a challenge for
therapeutic intervention due to their lack of expression of the
therapeutic targets estrogen receptor (ER), progesterone re-
ceptor (PR), and the ERBB2 oncogene (57, 65, 66), thus em-
phasizing the need for identification of new tumor-specific
markers.
The spatiotemporal expression pattern of Lbh during mouse
embryogenesis (8) led us to hypothesize that Lbh may be
controlled by morphogenic signaling pathways that orchestrate
cell specification and pattern formation. Using a combination
of molecular, mammalian tissue culture, mouse genetics, and
in silico analyses, we set out to identify the molecular pathways
operating upstream of LBH. In doing so, we discovered that
LBH expression in epithelial development is tightly controlled
by an antagonistic relationship between canonical Wnt/-cate-
nin and noncanonical Wnt7a signaling. Whereas LBH tran-
scription is induced by Wnt/-catenin signaling via four con-
served TCF/LEF binding sites in the LBH gene locus, this
induction is efficiently blocked by Wnt7a. Given the parallels
between Wnt signaling in development and cancer, we hypoth-
esized that LBH, as a canonical Wnt target gene, might be
deregulated in breast cancer. Indeed, we found that LBH is
aberrantly overexpressed in mammary tumors of MMTV-Wnt1
transgenic mice as well as in highly aggressive basal subtype
human breast cancers. Overexpression of Lbh in HC11 mam-
mary epithelial cells (MECs) further demonstrates that LBH
suppresses terminal cell differentiation, an effect that could
contribute to Wnt-induced tumorigenesis. Collectively, our
data suggest that LBH is a direct Wnt target gene that is
reactivated in a particularly lethal form of human breast
cancer.
MATERIALS AND METHODS
Genomic DNA isolation and plasmids. A Lambda gt11-129EV mouse genomic
DNA library (Stratagene) was screened with Lbh-specific cDNA probes (8).
Several overlapping genomic clones comprising approximately 30 kb of the
murine Lbh gene locus were isolated and mapped by restriction analysis. A
SexAI-NotI genomic fragment containing approximately 1.5 kb of Lbh promoter
region and 283 bp downstream of the transcriptional start site, including exon 1
(1469 to 283), was inserted into the XhoI-HindIII sites of a pGL3-luciferase
vector (Pwt). Lbh enhancer regions 1 and 2 (6365 to 6445 and 1240 to
2003, respectively) were PCR amplified and cloned individually into the KpnI
site of the Pwt plasmid construct upstream of the Lbh promoter to generate
constructs E1wt and E2wt. In vitro mutagenesis was performed to introduce
mismatch mutations into Lbh-specific TCF/LEF binding elements (TBEs) T1 to
T4 using the QuikChange II XL site-directed mutagenesis kit (Stratagene). The
sequence of mutagenic primers is shown in Table S1 in the supplemental mate-
rial. To generate a His-TCF4 expression vector, the TCF4 DNA binding domain
(DBD; residues 265 to 496) was PCR amplified using pGST-TCF4 (51) (gener-
ously provided by Tetsu Akiyama, University of Tokyo, Japan) as a template and
inserted into the BamHI-HindIII restriction sites of pET28A vector (Novagen).
Recombinant His-TCF4 was expressed in Escherichia coli and purified with
nickel beads (Novagen) according to the manufacturer’s protocol.
Electrophoretic mobility shift assays (EMSAs). Double-stranded DNA oligo-
nucleotides (30-mers) containing the genomic TBE sites T1 to T4 with flanking
sequences (see Table S1 in the supplemental material) were 5 end labeled with
32P, and 5,000 cpm/l of labeled probe was incubated with 1 g of recombinant
His-TCF4 protein in a total volume of 15 l binding buffer (25). For competition
and supershift experiments, His-TCF4 was preincubated with unlabeled DNA
oligonucleotides at a 400-fold excess or with 1 to 5 g of anti-6His tag antibody
(Abcam) for 10 min prior to addition of labeled probe. Samples were separated
on 5% nondenaturing polyacrylamide gels for 1 h at 400 V. Protein-DNA com-
plexes were detected by phosphorimaging on a Storm 840 scanner (Molecular
Dynamics).
Luciferase reporter assays. Luciferase reporter assays were performed as
described in reference 7 with the following modifications: 1 day prior to trans-
fection 2.0  105 cells were plated per well of a 12-well plate. Cells were
cotransfected with 100 ng of different luciferase reporter plasmids (Pwt, E1wt,
and E2wt or TOPFlash and FOPFlash) and 300 ng of pCDNA/-cateninS37Y
expression plasmid (kindly provided by Antonio Garcia de Herreros, Universitat
Pompeu-Fabra, Spain) using Lipofectamine 2000 reagent (Invitrogen). The fold
transactivation of each Lbh-luciferase construct represents the ratio between
normalized luciferase values of -cateninS37Y-cotransfected cells and of cells
transfected with the respective Lbh-luciferase constructs alone. For TOPFlash
reporter assays, fold activation represents the ratio between normalized TOP-
Flash and FOPFlash activities. All transfections were performed in duplicate,
and results of at least three independent experiments were statistically analyzed
using a paired Student t test.
Cell culture. Human mammary epithelial cells (HMEC) were obtained from
Clonetics; all other human breast epithelial tumor cell lines were from the
American Type Culture Collection (ATCC) and grown per the recommenda-
tions of these distributors. 293T and L-Wnt3a cells (ATCC) were cultured in
Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum
(FBS) and grown under standard conditions at 37°C in a 5% CO2 atmosphere.
Wnt3a-conditioned medium was prepared according to the distributor’s proto-
col. HC11 cells (kindly provided by Kermit Carraway) were grown in RPMI
medium supplemented with 10% FBS, 10 ng/ml insulin (Sigma), and 5 g/ml
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epidermal growth factor (EGF; Invitrogen). Stable polyclonal cell lines were
established by Lipofectamine transfection of HC11 cells with linearized
pCDNA3 empty vector or pCDNA3-NLbh plasmid (8) followed by selection in
200 g/ml of G418 (Invitrogen).
Wnt induction and RNAi. For time course experiments, 293T cells were cocul-
tured with Wnt3a-conditioned medium for 0, 4, 8, 16, and 24 h. Inhibition
experiments used 100 ng/ml of recombinant human DKK1, Wnt5a, or Wnt7a
(R&D Systems), which was added either alone for the indicated time points or
8 h prior to an 8-h treatment of cells with Wnt3a-conditioned medium. For RNA
interference (RNAi) studies, 4  105 293T cells were transfected with 100 nM
synthetic small interfering RNA (siRNA) specific for CTNNB1/-catenin or a
scrambled control sequence using Dharmafect 1 reagent (Dharmacon). Approx-
imately 65 h after siRNA transfection, 293T cells were trypsinized and trans-
ferred to a dish with twice the surface area to allow for growth. At 72 h
posttransfection, Wnt3a-conditioned medium was added for an additional 16 h.
After the cells were harvested, total RNA was isolated using TRIzol reagent
(Invitrogen) and treated with Turbo DNase (Ambion).
qPCR. cDNA was synthesized from 1 g DNase-treated total RNA using the
Transcriptor first-strand cDNA synthesis kit (Roche). Quantitative real-time
PCRs (qPCRs) were carried out in 20 l using SYBR green Master Mix (NEB)
containing 10 nM 6-carboxyfluorescein (Sigma) as a reference dye, 50 to 100 ng
of cDNA, and 2 M primers. The reactions were performed in triplicate on a
Bio-Rad iCycler and quantified using the iCycler iQ software. The relative
quantities of LBH, DKK1, and -catenin mRNA were determined for each
sample based on the threshold cycle (CT) value normalized to the corresponding
values for GAPDH. For sequences of the qPCR primers, see Table S1 in the
supplemental material.
Mice, histology, in situ hybridization (ISH), and X-Gal staining. MMTV-Wnt1
[B6SJL-Tg(Wnt1)1Hev/J] and TopGal [Tg(Fos-lacZ)34Efu/J] transgenic mice
were purchased from Jackson Laboratories (Bar Harbor, ME). The Wnt7a/
and Lmx1b/ mice were generously provided by Andy McMahon, (Harvard
University, Boston, MA) and Randy Johnson (Baylor University, Houston, TX).
Mice were bred and maintained in accordance with the guidelines set forth by the
National Institutes of Health Guide for the Care and Use of Laboratory Animals,
published by the U.S. Public Health Service. All experimental protocols were
approved by the Institutional Animal Care and Use Committee at the University
of Miami. Whole-mount in situ RNA hybridization and X-Gal (5-bromo-4-
chloro-3-indolyl--D-galactopyranoside) staining of embryos and sections were
performed as previously described (8). Moreover, 14-m cryosections of snap-
frozen mouse mammary glands or 5-m paraffin sections of MMTV-Wnt1 mam-
mary tumors were hybridized with a mouse Lbh-specific antisense probe (8).
Western blot analysis. Mammary epithelial cells (MECs) from mammary
glands of wild-type mice were isolated via proteolytic digestion with 100 units/ml
hyaluronidase (Sigma) and 2 mg/ml collagenase A (Roche) in 15 ml DMEM for
3 h at 37°C with gentle agitation followed by washing in DMEM plus 5% FBS.
Tumors from MMTV-Wnt1 transgenic mice were snap-frozen in liquid nitrogen
and mechanically pulverized. Isolated MECs and ground tumors were lysed in
RIPA lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 1 mM EDTA, 0.1% SDS) containing protease inhibitors (Am-
resco). For Western blot analysis a total of 25 g protein extract per sample was
separated by SDS-PAGE, blotted on nitrocellulose membrane, and incubated
with the following antibodies in TBST (20 mM Tris HCl, pH 7.5, 140 mM NaCl,
0.1% Tween 20) plus 5% nonfat dry milk: a rabbit polyclonal Lbh antibody raised
against murine Lbh and purified by Melon Gel IgG purification (Pierce; 1:1,000),
polyclonal keratin 5 (Covance; 1:10,000), polyclonal keratin 8/18 (Progen;
1:2,000), monoclonal -actin (AC-15, Sigma A5441; 1:50,000), and anti-rabbit,
anti-mouse, or anti-guinea pig horseradish peroxidase (HRP)-coupled secondary
antibodies (Amersham, Sigma; 1:10,000).
Immunofluorescence. Cells were grown overnight on BD Biosciences culture
slides at a density of 2  105 cells per well and induced with Wnt3a-conditioned
medium for 6 h. Cells were fixed with 2% paraformaldehyde in phosphate-
buffered saline (PBS) for 15 min at room temperature, followed by cell perme-
abilization in 0.3% Triton X-100 in PBS. Cells were blocked for 1.5 h in PBS plus
10% normal goat serum (NGS) and incubated with -catenin antibody (BD
Biosciences; 1:200) followed by subsequent incubation with anti-mouse Cy3
(Jackson ImmunoResearch; 1:400). Cells were mounted in Slowfade plus DAPI
(4,6-diamidino-2-phenylindole; Molecular Probes) according to the manufac-
turer’s protocol. Images were taken on a DMRI Leica inverted microscope.
Chromatin immunoprecipitation (ChIP). HC11 cells were grown to 70%
confluence prior to addition of Wnt3a-conditioned medium for 3 h. Cells were
fixed in a final concentration of 1% formaldehyde for 10 min at room temper-
ature followed by a quenching of fixative with 125 mM glycine. Cells were
incubated for 10 min on ice in swelling buffer (5 mM PIPES [piperazine-N,N-
bis(2-ethanesulfonic acid)], pH 8.0, 85 mM KCl, 1% NP-40) at a concentration
of 5  107 cells/ml followed by Dounce homogenization 15 times. Nuclei were
pelleted at 2,500 rpm for 5 min and resuspended in sonication buffer (50 mM
Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) at a concentration of 1 108 cells/ml.
Sonication of cells for 6 pulses of 15 s each on ice-water at 50% power on a
Misonix sonicator resulted in chromatin fragments of an average length of 1 kb.
Lysates were cleared for 10 min at top speed. For each IP reaction, 1  107 cell
equivalents were diluted to a 1-ml total volume in dilution buffer (0.01% SDS,
1.1% Triton X-100, 1.1 mM EDTA, 16.7 mM Tris-HCl, pH 8, 167 mM NaCl) and
precleared for 2 h with 40 l protein A/G Sepharose beads (GE Healthcare).
Cleared lysates were incubated overnight with 5 g of normal rabbit IgG, anti-
acetyl-histone 3, or anti--catenin antibodies (Upstate). Thereafter, precipita-
tion of immunocomplexes was performed according to the Upstate EZ ChIP
protocol. PCRs for 35 cycles were carried out using Phusion polymerase
(Finnzymes).
Cell proliferation and differentiation assays. For proliferation assays, 2,000
cells were seeded in triplicate on 96-well plates. Two hours postplating, 20 l of
CellTiter 96 AQueous One cell proliferation assay reagent (Promega) was added
to wells containing cells and blank medium controls. Reagent was applied at the
same time daily, and absorbance at 492 nm was measured 2 h later on a micro-
plate reader for 7 days. Background was eliminated by subtracting values of
medium controls. Differentiation of HC11 cells was carried out for 3 days ac-
cording to the method in reference 3.
Gene expression analysis. Affymetrix gene expression data representing a total
of 1,107 primary breast tumors from six previously published microarray studies
(16, 21, 34, 56, 68, 76) were integrated as described previously using a mean-
batch centering method (5, 63). Centroid prediction (11) was used to assign the
tumors from each data set to the five Norway/Stanford subtypes (Basal, Luminal
A, Luminal B, ERBB2, and Normal-like [57, 65, 66]). Centered average linkage
clustering of the integrated tumor data sets was performed using the Cluster (23)
and TreeView programs as described previously (65).
RESULTS
Identification of functional Wnt-responsive elements in the
Lbh gene locus. To elucidate the molecular pathways acting
upstream of Lbh, we screened murine Lbh genomic sequences
for potential transcription factor binding sites. This in silico
search identified four conserved putative TCF/LEF binding
elements (TBEs) in the Lbh gene locus. Two TBEs with the
consensus motif 5-CTTTG(A/T)(A/T)-3 (75) were located
within an enhancer region (E1) at bp 6245 (T1) and 6195
(T2) upstream of the Lbh transcriptional start site (Fig. 1A). In
addition, two consensus TBEs were found in an enhancer (E2)
contained within the first intron of the Lbh gene at bp positions
1558 (T3) and 2145 (T4) (Fig. 1A). To directly assay for
TCF binding to these sites, electrophoretic mobility shift assay
(EMSA) was performed. Recombinant TCF4 protein bound
with high affinity to all Lbh-specific TBEs (T1 to T4) but not to
an unspecific oligonucleotide (Fig. 1B). TCF4 binding to these
sites was efficiently competed by addition of a 400-fold excess
of unlabeled wild-type () oligonucleotide but not by addition
of a 400-fold excess of mutant (m) oligonucleotide (Fig. 1B).
Furthermore, TCF4-specific protein-DNA complexes were su-
pershifted with increasing amounts of an antibody against re-
combinant TCF4 (Fig. 1C).
Subsequently, cell-based reporter assays were performed to test
whether the Lbh gene-specific TBE sites (T1 to T4) were func-
tionally responsive to overexpression of -catenin, which is the
Wnt-inducible component of the TCF/-catenin transcriptional
complex. HC11 mouse mammary epithelial cells were used be-
cause this cell line abundantly expresses TCF4 but has low en-
dogenous Wnt/-catenin signaling activity (17). The Lbh en-
hancer regions E1 and E2 were cloned individually into a
promoter-luciferase construct (Pwt) upstream of approximately
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1.5 kb of murine Lbh gene promoter sequences that do not
contain any apparent consensus binding sites for TCF/-catenin.
The three Lbh-luciferase reporter constructs (Pwt, E1wt, and
E2wt) were cotransfected with a pCDNA plasmid vector express-
ing constitutively active -catenin (-cateninS37Y). As shown in
Fig. 1D, Lbh-luciferase constructs containing wild-type TBE sites
(E1wt and E2wt) were induced by -cateninS37Y approximately
14- to 18-fold. The basal Lbh promoter-luciferase construct (Pwt)
also showed transcriptional activation despite the lack of TBEs,
indicating that -catenin may also have indirect effects on Lbh
promoter activity. Most importantly, however, mutations of both
T1 and T2 together (E1t1-2) or of T3 and T4 either individually
or in combination (E2t3, E2t4, and E2t3-4) significantly reduced
(2.5- to 3-fold; P 0.02) transcriptional activation of Lbh report-
ers by -cateninS37Y (Fig. 1D). Mutation of either T1 or T2 alone
had little effect, suggesting that binding of a TCF/-catenin tran-
scriptional complex to only one of these sites is sufficient for
activity of this enhancer (E1). These data suggest that Lbh is
FIG. 1. Identification of functional TCF binding elements (TBEs) in the mouse Lbh gene locus. (A) Schematic of genomic Lbh promoter/
enhancer sequences in the 5 upstream region and the first intron between exons 1 and 2. The positions of four putative conserved TBE sites (T1
to T4) predicted by MatInspector (Genomatix) and/or rVista (http://rvista.dcode.org) computer software are shown in relationship to the
transcriptional start site (1). Sequences of T1 to T4 in comparison with the TBE consensus site (75) are indicated. S, sense strand; AS, antisense
strand. (B) Electrophoretic mobility shift assay (EMSA) showing high-affinity binding of recombinant His-tagged TCF4 protein to T1 through T4.
In oligonucleotide competition experiments, no competitor oligonucleotide (), a 400-fold excess of unlabeled wild-type TBE oligonucleotide (),
or mutant TBE oligonucleotide (m) was added to gel shift reaction mixtures. Migration of free probe (brackets) and of TCF4 protein-DNA
complexes (solid and open arrows) is indicated. (C) Supershift of His-TCF4 binding to the T3 (1558) site with 1 to 5 g of antibody to the his
tag epitope (-His). (D) Transient reporter assays in HC11 mouse mammary epithelial cells. Luciferase (Luc) reporter constructs containing
different murine Lbh promoter/enhancer sequences (P, E1, and E2) with wild-type (wt) and mutant TBEs (t1 to t4) as shown schematically were
cotransfected with a pCDNA construct expressing constitutively active -catenin (-cateninS37Y). Values represent relative fold increase of
transcriptional activation for each construct (see Materials and Methods). *, P  0.02.
4270 RIEGER ET AL. MOL. CELL. BIOL.
activated by the canonical Wnt pathway at the transcriptional
level via high-affinity TCF binding elements located within up-
stream and intronic enhancer regions of the Lbh gene.
Expression of endogenous LBH is upregulated by canonical
Wnt signaling in 293T cells. To further test whether LBH is a
bona fide Wnt/-catenin target gene, we examined whether
endogenous LBH mRNA expression was responsive to Wnt.
Human 293T embryonic kidney epithelial cells were cocul-
tured with Wnt3a-conditioned medium (here referred to as
Wnt3a), and mRNA levels of LBH, as well as of a known Wnt
target gene, DKK1 (13, 26, 51), were assayed over a 24-h time
course using quantitative real-time PCR (qPCR) analysis. In-
duction of LBH was detectable within 4 h of Wnt3a treatment
and reached a maximum at 16 h (	4-fold increase) (Fig. 2A).
DKK1 was induced to a smaller degree, and its induction was
delayed compared to that of LBH (Fig. 2A). Induction of both
LBH and DKK1 mRNA expression by Wnt3a was efficiently
blocked by recombinant DKK1 protein (Fig. 2A and C), a
potent inhibitor of canonical Wnt/-catenin signaling (50).
Moreover, Wnt3a-mediated induction of LBH and DKK1 was
abrogated by depletion of -catenin expression using RNAi,
while scrambled control siRNA had no effect (Fig. 2B). These
results reinforce the notion that LBH is a direct transcriptional
target of the canonical Wnt signaling pathway.
To investigate whether Wnt ligands that signal through non-
canonical pathways could also induce LBH gene expression,
293T cells were treated for 16 h with recombinant Wnt5a or
Wnt7a (Fig. 2C). In contrast to Wnt3a, both Wnt5a and Wnt7a
treatment alone did not induce LBH but modestly reduced
baseline LBH and DKK1 expression (Fig. 2C). Since Wnt5a
has previously been shown to inhibit Wnt3a-induced canonical
Wnt signaling (48), we also examined LBH gene expression in
cells treated with both Wnt3a and the individual noncanonical
Wnt ligands. Surprisingly, Wnt7a strongly inhibited LBH and
DKK1 induction by Wnt3a, whereas Wnt5a failed to block
Wnt3a-mediated induction of these genes (Fig. 2C). Thus,
LBH is specifically induced by canonical Wnt signaling,
whereas noncanonical Wnt7a signaling has an antagonistic ef-
fect on LBH expression and its induction by Wnt3a.
Lbh is downstream of Wnt signaling in mouse embryonic
limb development. As Lbh was identified as a developmental
regulatory gene (8), we next examined whether Wnt signaling
might play a role in regulating Lbh expression during verte-
brate embryonic development. We have previously shown that
during early mouse limb development Lbh is expressed in the
apical ectodermal ridge (AER) and in a ventral pattern in
non-AER limb bud ectoderm (8). These ectodermal domains
provide the cues for proximo-distal and ventral limb pattern-
ing, respectively (14, 70), and have recently been shown to be
patterned by canonical Wnt/-catenin signaling in concert with
the Bmp pathway (Fig. 3A) (4, 67). Conversely, Wnt7a, which
is expressed and secreted from dorsal limb ectoderm, induces
dorsal limb differentiation through a noncanonical pathway
involving Lmx1b upregulation in the underlying dorsal limb
mesenchyme (Fig. 3A and B, panel iii) (37, 55). Thus, we
reexamined Lbh expression in relationship to the different Wnt
signaling activities during crucial stages of mouse embryonic
limb development.
As shown in Fig. 3B, panel i, Lbh expression was exclusively
confined to the ventral limb and AER ectoderm of embryonic
FIG. 2. Regulation of endogenous LBH mRNA expression in human
293T cells by Wnt signaling. (A to C) qPCR analysis measuring relative
mRNA levels of LBH, DKK1, and -catenin normalized to GAPDH
mRNA levels. All values represent means
 standard deviations (n 3).
(A) Time course analysis showing induction ofLBH andDKK1 expression
in response to Wnt3a. Cells were treated with Wnt3a-conditioned me-
dium (Wnt3a) for the indicated time points. Wnt3a-mediated induction of
both genes was inhibited by coadministration of recombinant Wnt inhib-
itor DKK1 (100 ng/ml), which was added 8 h prior to an 8-h treatment of
cells with Wnt3a. (B) siRNA knockdown of -catenin abolishes Wnt3a-
induced upregulation ofLBH, confirming activation ofLBH expression by
the canonical Wnt pathway. At 72 h posttransfection, 293T cells were
treated with vehicle () or with Wnt3a-conditioned medium () for an
additional 16 h. Note the reduction of -catenin mRNA levels to less than
20% of endogenous expression levels in -catenin (-cat) siRNA-trans-
fected cells. (C) Wnt7a, but not Wnt5a, inhibits Wnt3a-induced activation
of LBH and DKK1. Cells were treated for 16 h with recombinant Wnt5a
or Wnt7a proteins (100 ng/ml) individually or in conjunction with Wnt3a.
As a control, cells were treated for 16 h with bovine serum albumin (BSA)
vehicle.
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day 10.5 (E10.5) wild-type embryos as revealed by whole-
mount in situ RNA hybridization analysis. Similarly, canonical
Wnt activity was detected predominantly in the AER and ven-
tral limb ectoderm, as evident by lacZ expression in TopGal
embryonic limbs at the same stage, although some cells in the
most distal dorsal ectoderm also expressed lacZ (Fig. 3B, panel
ii). Moreover, genes regulated by canonical Wnt signaling,
such as Fgf8 and En1 (37), were exclusively restricted to the
AER and/or ventral limb ectoderm, respectively, and over-
lapped with Lbh expression in these ectodermal domains (Fig.
3B, panels i, iv, and v). The pattern of Lbh expression in
embryonic limb ectodermal cells is also similar to that de-
scribed for other Wnt/-catenin target genes, including Dkk1
and axin2, which are expressed in the AER (1, 67). In contrast,
expression of Lbh, as well as of En1 and Fgf8, was mutually
exclusive with the Wnt7a expression domain in dorsal limb
ectoderm (Fig. 3B, panels i and iii to v).
The complementary expression patterns of Wnt7a and Lbh
(Fig. 3B, panels iii and i), as well as repression of LBH by
Wnt7a in tissue culture cells (Fig. 2C), prompted us to test
potential Wnt7a effects on Lbh expression in vivo. Lbh expres-
sion was examined in mouse mutants in which the noncanoni-
cal Wnt7a pathway was rendered inactive by gene targeting
(15, 55). Remarkably, in Wnt7a/ mutant mice and animals
lacking the Wnt7a downstream transcriptional regulator
Lmx1b (Lmx1b/), Lbh was ectopically expressed in the distal
dorsal limb ectoderm (Fig. 3C, panels ii and iii). In contrast,
Lbh exhibited a normal ventral expression pattern in wild-type
littermates (Fig. 3C, panel i). Taken together, these develop-
mental genetic studies provide the first functional evidence
that Lbh expression in vivo coincides with canonical Wnt sig-
naling activity and that it is repressed by noncanonical Wnt7a-
Lmx1b signaling during embryonic limb development.
Lbh is expressed in postnatal mammary gland development,
and levels are elevated in mammary tumors of MMTV-Wnt1
transgenic mice. To test our hypothesis that Lbh might be
implicated in Wnt-induced tumorigenesis, we examined Lbh
expression in MMTV-Wnt1 transgenic mice, a mouse model
for Wnt-induced breast cancer (Fig. 4) (71). Moreover, since
the expression pattern of Lbh in normal adult breast tissue was
not known, we analyzed Lbh expression during postnatal
mouse mammary gland development using RNA in situ hybrid-
ization and Western blot analyses.
In postpubertal (7 weeks) virgin female mammary glands,
expression of Lbh was restricted to stromal, basal-myoepithe-
lial, and terminal end bud (TEB) mammary epithelial cells
(Fig. 4A and data not shown). In contrast, Lbh was absent from
ductal luminal mammary epithelial cells at all postnatal devel-
opment stages analyzed (Fig. 4A). During pregnancy, Lbh lev-
els drastically increased and Lbh transcripts were primarily
detected in the proliferating lobulo-alveolar compartment, a
pattern that was maintained during early involution (Fig. 4A
and B). Notably, Lbh expression was virtually absent in lactat-
ing mammary glands, suggesting that Lbh is not expressed in
terminally differentiated secretory mammary epithelial cells
(Fig. 4A and B). Most remarkably, Lbh expression levels were
significantly elevated (2.8- to 4.2-fold) in 9 out of 10 mammary
tumors from different MMTV-Wnt1 transgenic mice compared
to nonpregnant mammary glands, HC11 cells, and mammary
epithelial cells isolated from equiparous wild-type littermates
FIG. 3. Lbh expression during mouse embryonic limb bud forma-
tion is regulated by Wnt signaling. (A) Model for the genetic regula-
tion of dorsoventral (D to V) limb patterning and apical ectodermal
ridge (AER) formation. Wnt3 (Wnt3a in chicken embryo) and -cate-
nin act upstream of the Bmp pathway to induce En1 gene expression
(red) in the ventral limb and AER ectoderm. En1 is required for
ventral limb specification and restricts expression of Wnt7a (green) to
the dorsal ectoderm. Wnt7a induces dorsal limb specification through
induction of Lmx1b (light green) in the underlying dorsal mesoderm.
Canonical Wnt/-catenin signaling also directly induces expression of
Fgf8 (blue) in the AER and is required for AER maintenance (4, 37,
45, 67). (B) Whole-mount RNA in situ hybridization analysis of E10.5
wild-type mouse embryonic limbs and transverse sections thereof
showing that LBH expression in AER (brackets) and ventral limb
ectoderm (i) overlaps with (ii) canonical Wnt activity, as detected by
X-Gal staining of TopGal reporter mice at E10.5, as well as with
expression of known Wnt/-catenin-induced genes En1 (iv) and Fgf8
(v). In contrast, Wnt7a expression in dorsal limb ectoderm (iii) is
mutually exclusive with expression of Lbh. (C) Lbh is ectopically ex-
pressed in the dorsal limb ectoderm of Wnt7a/ (ii) and Lmx1b/
(iii) mouse patterning mutants at E10.5 (red arrows), compared to
wild-type limbs (i). D, dorsal; V, ventral.
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(Fig. 4A to D and data not shown). Moreover, in MMTV-Wnt1
tumors, which phenocopy human basal breast cancer (30), Lbh
expression correlated with expression of the basal marker ker-
atin 5, whereas it inversely correlated with expression of the
luminal markers keratin 8 and 18 (Fig. 4C). Thus, Lbh is
expressed at normal levels in basal and proliferative alveolar
mammary epithelial cells during normal mammary gland de-
velopment, whereas it is overexpressed in Wnt-induced basal
breast epithelial tumors.
Lbh overexpression suppresses the differentiation of HC11
mammary epithelial cells. As we found Lbh expression specif-
ically in cellular targets of canonical Wnt signaling during
normal mammary gland tissue homeostasis (9, 69, 72) and Lbh
over expression in Wnt-induced mammary tumors (Fig. 4), we
further investigated the functional relationship between Wnt/
-catenin signaling and Lbh in a cell culture system for mam-
mary epithelial development. HC11 was chosen because it is
one of few existing nontransformed mammary epithelial cell
lines that can be induced to differentiate in vitro with lactogenic
hormones (3). Moreover, overexpression of different Wnt li-
gands has been shown to lead to cellular transformation of
these cells (31, 32). To test whether Lbh could be downstream
of canonical Wnt signaling in mammary epithelial cells, we
treated HC11 cells, which do not express Lbh (Fig. 4), with
Wnt3a. Wnt3a treatment resulted in nuclear localization of
-catenin as well as a rapid increase in Lbh mRNA levels (Fig.
5A and B). In addition, ChIP analysis showed that the Lbh
gene regulatory sequences T1 to T4 (Fig. 1A) were occupied by
endogenous -catenin in Wnt3a-treated cells but not in un-
treated control cells (Fig. 5C and data not shown).
Having demonstrated that Lbh is a direct transcriptional
target of Wnt/-catenin in HC11 cells, we asked whether over-
expression of Lbh elicits some of the same effects that have
been reported for overexpression of Wnt ligands in this cell
line (31, 32). Several polyclonal HC11 cell lines stably express-
ing Lbh (Lbh c1 and c2) were generated by transfection with a
pCDNA3-Lbh plasmid, and Lbh overexpression was confirmed
by qPCR and Western blot analyses (Fig. 5D). No Lbh expres-
sion was detectable in vector control-transfected cells or in the
parental HC11 cells (Fig. 4D and 5D). Although ectopic Lbh
expression did not result in cell transformation as determined
by soft agar assays (data not shown), the growth rates of Lbh-
expressing HC11 cells were significantly increased compared to
those of vector control cells (Fig. 5E). Moreover, whereas
differentiation induction with prolactin and dexamethasone in-
creased mRNA expression of the milk protein -casein in
parental and vector control cells, induction of -casein in re-
sponse to these lactogenic hormones was lost in HC11-Lbh
FIG. 4. Lbh expression during normal mouse mammary gland development and overexpression in Wnt-induced mammary tumors. (A) RNA
in situ hybridization analysis of sagittal cryosections of 7-week virgin, 13-day pregnant, 12-day lactating, and 4-day involuting normal mammary
glands (original magnification, 40). Lbh is expressed in basal-myoepithelial, terminal end bud, and stromal cells in virgin mammary glands, as
well as in the lobulo-alveolar units during pregnancy and involution. Note that Lbh is not expressed in luminal epithelial cells or in lactating
mammary glands. (B) Western blot analysis depicting Lbh protein levels during normal mammary gland development at the same stages as in panel
A. (C and D) RNA in situ hybridization (C) and Western blot analysis (D) showing elevated Lbh expression levels in mammary tumors of
MMTV-Wnt1 transgenic mice (T1 to T6) compared to HC11 and isolated wild-type (WT) mammary epithelial cells (MEC). Basal keratin 5 (Krt
5) and luminal keratin 8/18 (Krt 8/18) mammary epithelial markers, as well as a -actin loading control, are shown. Quantification of Lbh protein
levels by densitometry normalized to -actin values is shown in the bottom panel. N/A, not applicable.
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cells (Fig. 5F). Thus, overexpression of Lbh promotes cell
proliferation and blocks terminal differentiation of HC11
mammary epithelial cells.
LBH is overexpressed in highly invasive ER-negative, basal
subtype human breast cancers. To further examine whether
LBH might be deregulated in human breast cancer, meta-
analysis of six Affymetrix gene expression data sets comprising
1,107 primary human breast cancers was performed as previ-
ously described (63). These data represent the five “intrinsic”
breast tumor subtypes normal-like, luminal A, luminal B,
ERBB2 positive, and basal-like (65), which can be distin-
guished by specific gene signatures and differences in clinical
outcome, with basal-like breast cancers having the worst prog-
nosis (Fig. 6) (57, 65, 66). Strikingly, LBH expression was
significantly associated with aggressive, poorly differentiated
basal type carcinomas. Almost half (45%) of the basal breast
tumors had high LBH expression levels (Fig. 6B). In contrast,
elevated LBH was observed in far smaller proportions of nor-
mal-like (24%), luminal A (16%), luminal B (23%), and
ERBB2 (27%) breast carcinomas (Fig. 6B). Moreover, a
strong inverse correlation was observed between LBH and
estrogen receptor alpha (ESR1) expression (Fig. 6A; see also
Fig. S1 in the supplemental material) (R0.29, P 0.0001),
whereas no significant correlation existed with ERBB2 status
(see Fig. S1) (R  0.01). Most remarkably, however, LBH
expression in breast tumors strongly correlated with the basal
marker keratin 5 and canonical Wnt pathway genes, such as
SFRP1, TCF4, TCF7, and DKK3 (Fig. 6A; see also Fig. S1) (P
 0.0001). These data highlight LBH as a novel molecular
marker for difficult-to-treat ER-negative basal type breast can-
cer and suggest that LBH deregulation in breast cancer could
be a consequence of oncogenic Wnt signaling.
The lack of suitable antibodies currently precludes analysis
of LBH protein expression in clinical specimens. Therefore, we
analyzed human breast carcinoma cell lines to validate our
findings. We first queried published Affymetrix gene expres-
sion data from 51 human breast cancer cell lines (49) to con-
firm the existence of a relationship between LBH expression
and breast cancer subtype. Expression of LBH was significantly
higher in both the basal A and basal B cell line subtypes than
in those classified as luminal (P 0.007) (Fig. 7A). Specifically,
50% of the basal A (n  12) and 29% of the basal B (n  14)
cell lines had high (upper quartile) expression of LBH, com-
pared to only 12% of luminal (n  25) cell lines (Fig. 7A).
Similar results were observed in a more recent cDNA microar-
ray study of breast cancer cell line gene expression (36) (Fig.
7A), which also demonstrated significantly higher expression of
LBH in the basal A and basal B cell lines than in the luminal
FIG. 5. Wnt/-catenin-mediated induction and ectopic expression of Lbh in HC11 mammary epithelial cells. (A) Immunofluorescence analysis
showing nuclear translocation of -catenin in HC11 cells treated with Wnt3a-conditioned medium (Wnt3a) for 6 h but not in untreated cells.
(B) qPCR analysis measuring rapid induction of Lbh in cells treated with Wnt3a at the indicated time points. (C) ChIP analysis of -catenin
occupancy of endogenous Lbh gene regulatory sequences (T1/T2 and T4) in cells treated with Wnt3a for 3 h. DNA derived from sheared chromatin
fragments from untreated and Wnt3a-treated cells immunoprecipitated with antibodies to -catenin, acetyl-histone 3, and normal rabbit IgG was
quantified by semiquantitative reverse transcription PCR (RT-PCR). As a control, 1% of input chromatin was used. (D) qPCR (top) and
Western blot analyses (bottom) of two polyclonal cultures (c1 and c2) of HC11 cells stably expressing pCDNA3-Lbh or pCDNA3 vector alone,
showing overexpression of Lbh in HC11-Lbh cultures. -Actin was used as a loading control. (E) Ectopic expression of Lbh increases cell growth
as assessed by CellTiter 96 AQueous One solution cell proliferation assay. Values represent the mean values; error bars represent the standard
deviations (n  3). Student’s t test was used to evaluate significance: *, P  0.01; **, P  0.001. (F) Semiquantitative RT-PCR (top) and qPCR
(bottom) analyses measuring induction of the terminal differentiation marker -casein. Confluent cell cultures were treated for 3 days with normal
growth medium or serum-free differentiation medium containing 5 g/ml prolactin and 1 M dexamethasone (PRL/DEX). qPCR values were
normalized to Gapdh. All values represent means 
 standard errors of the means (n  3).
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cell line (42%, 40%, and 12% of cells with high expression,
respectively).
We next examined LBH expression in a panel of 13 estab-
lished human breast cancer cell lines by using qPCR and West-
ern blot analysis. High levels of LBH expression were detected
only in the ER-negative basal subtype breast tumor cell lines
HCC1395, MDA-MB-231, and HCC1187 (Fig. 7B and D). In
contrast, none of the ER-positive lines (MCF7, T47D, ZR-
75-1, and MDA-MB-361) or ER-negative (SK-BR-3) luminal
cell lines expressed LBH at detectable levels (Fig. 7B and D).
Furthermore, LBH protein was not detected in normal human
mammary epithelial cells (HMEC) or in nonmalignant
MCF10A cells (Fig. 7D). Thus, consistent with our gene ex-
pression analysis in primary breast tumors, LBH expression in
breast cancer-derived cell lines correlated with an invasive
basal carcinoma phenotype and inversely correlated with ex-
pression of the good prognostic marker ER.
LBH deregulation in breast cancer may be due to aberrant
Wnt/-catenin pathway activation. To begin to investigate the
mechanisms underlying LBH deregulation in breast cancer, we
queried comparative genomic hybridization array (aCGH)
data that were available for these breast tumor cell lines. Only
one of three LBH-overexpressing basal tumor cell lines
(HCC1395) had a modest increase in LBH copy number (Fig.
7C). Moreover, aCGH analysis of primary breast tumor data
sets did not show a significant correlation between increased
LBH copy number and LBH overexpression in basal subtype
tumors (data not shown), suggesting that changes in LBH gene
dosage play a minor role in LBH dysregulation in basal breast
carcinomas. To further test whether LBH overexpression may
be a consequence of aberrant Wnt signaling, we measured
endogenous Wnt signaling activity in LBH-positive breast tu-
mor cell lines using TOPFlash reporter assays. Strikingly, 2 out
of 3 of these cell lines (HCC1187 and HCC1395) displayed
increased Wnt/-catenin signaling activity, similar to HC11
cells transfected with pCDNA/-cateninS37Y (Fig. 7E). Consis-
tent with previous studies (74), no detectable Wnt activity was
measured in MDA-MB-231 cells, nor in HC11 cells, which
served as a negative control. Furthermore, treatment of
HCC1395 cells with DKK1 inhibitor blocked LBH expres-
sion, indicating that expression of LBH in this breast tumor
cell line is dependent on Wnt/-catenin signaling (Fig. 7F).
Finally, we explored whether Wnt7a could serve as a means
to inhibit LBH expression in basal breast tumor cells. Re-
markably, treatment of HCC1395 cells with Wnt7a effi-
ciently suppressed mRNA expression of LBH as well as of
DKK1 (Fig. 7F). Thus, aberrant canonical Wnt signaling, at
least in part, is responsible for LBH overexpression in basal
subtype breast carcinoma cells.
DISCUSSION
Previous overexpression studies with mice and chicks have
clearly defined a pivotal role of the novel vertebrate transcrip-
tional regulator LBH in embryonic development and congen-
ital disease (7, 8, 19). However, the molecular mechanisms
upstream of LBH and its role in adult development have re-
mained obscure. The present study links LBH for the first time
to the Wnt signaling pathway, an essential developmental and
oncogenic signaling network, as well as implicating LBH over-
expression in breast cancer.
We demonstrate through cell-based induction, RNAi knock-
down of -catenin, and reporter assays, as well as through mo-
lecular in vitro EMSA and in vivo ChIP analysis, that LBH is a
direct transcriptional target of the canonical Wnt/-catenin path-
way. Specifically LBH is upregulated via binding of TCF/-cate-
FIG. 6. LBH gene expression in human breast cancer correlates with ER-negative, basal-like tumor subtype. (A) Meta-analysis of 1,107 human
primary breast carcinoma samples from six published Affymetrix data sets (63) showing a strong positive correlation of LBH with basal tumor type,
as well as expression of keratin 5 (KRT5) and Wnt pathway genes SFRP1, TCF7, TCF4, and DKK3. In contrast, the LBH signature inversely
correlates with estrogen receptor alpha (ESR1) expression. Clustering of tumor subtypes—basal (red), ERBB2 (purple), luminal A (dark blue),
luminal B (light blue,) and normal-like (green)—was done according to reference 66. Red, high expression; green, low expression. (B) Table
showing the proportion of breast cancer specimens with high levels (overall upper quartile) of LBH mRNA expression in individual tumor subtypes.
P  0.0000014 (chi-squared test).
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nin transcriptional complexes to four functional conserved TCF/
LEF binding sites (75) in two Lbh enhancer regions. A basal Lbh
promoter-reporter construct (Pwt) containing no TBE sites also
showed transcriptional activation by -cateninS37Y, which could
be due to association of -catenin with p300 or CREB (29, 78),
each of which has binding sites in the basal Lbh promoter (data
not shown). Interestingly, LBH induction by Wnt3a in 293T cells
consistently occurred to a greater extent (4-fold versus 2-fold
induction) and with more rapid kinetics than for the known ca-
nonical Wnt target gene DKK1 (13, 26, 51). Given that Wnt
ligands act as morphogens and that different concentrations of
Wnts elicit distinct cellular responses (81), these results might
FIG. 7. Validation of LBH expression and Wnt responsiveness in human breast tumor cell lines. (A) LBH mRNA expression is significantly higher
in basal rather than in luminal breast carcinoma cell lines classified according to tumor subtype (36, 49). Values represent the means, and error bars
represent the standard errors. (n), number of samples per tumor subtype; NS, not significant. (B) qPCR analysis of relative LBH mRNA expression in
a panel of human breast tumor cell lines showing overexpression of LBH in HCC1395, MDA-MB-231, and HCC1187 tumor cells. Cell lines are arranged
by tumor subtype (49). All measurements were performed in triplicate, and expression levels were normalized to mRNA levels of GAPDH. (C) Com-
parative genomic hybridization array (aCGH) analysis of the same breast tumor cell lines as those in panel B. (D) Western blot analysis detecting
expression of LBH protein exclusively in invasive ER-negative basal type breast cancer lines but not in two nontransformed (normal) mammary epithelial
cell lines or in low-invasive breast tumor cell lines. -Actin was used as a loading control. (E) TOPFlash reporter assay detects Wnt signaling activity in
LBH-expressing HCC1395 and HCC1187 cells but not in MDA-MB-231 cells. HC11 and HC11 transiently transfected with pCDNA3/-cateninS37Y were
used as negative and positive controls, respectively. Values represent the mean ratios of TOPFlash over FOPFlash activity 
 standard deviations.
(F) Administration of recombinant DKK1 and Wnt7a (100 g/ml) for the indicated time points strongly inhibits LBH and DKK1 mRNA expression in
HCC1395 cells as revealed by qPCR analysis. Values represent means 
 standard errors of the means (n  3).
4276 RIEGER ET AL. MOL. CELL. BIOL.
indicate that differences in the numbers and affinities of TBE sites
in LBH versus DKK1 may be a critical determinant of when and
where these Wnt target genes are turned on. Most importantly,
the placement of LBH downstream of Wnt appears to be “uni-
versal” in mammalian epithelial development, as it was observed
in both embryonic (293T, limb ectoderm) and adult (postnatal
mammary gland, HC11 cells) epithelial systems, as well as in
epithelial neoplasia (MMTV-Wnt1 mammary tumors, human
breast cancer cell lines). Such an intimate relationship between
Wnt/-catenin and other target embryonic transcription factors
does not always exist. For instance, TWIST, a transcriptional
regulator of mesenchymal cell fate and inducer of epithelial-
mesenchymal transition (EMT) during breast metastasis, is up-
regulated in mouse Wnt-induced breast tumors (22, 31, 79) but
unlike LBH is not expressed in normal epithelial development.
Moreover, the Lbh expression pattern overlapped not only with
Wnt/-catenin signaling activity during embryonic limb ectoderm
development but also with the expression patterns of several Wnt
ligands (9, 10, 24) during postnatal mammary gland development.
Wnt has been shown to stimulate the growth of TEB cells during
mammary gland branching morphogenesis, the expansion of the
lobulo-alveolar compartment during pregnancy, and the self-re-
newal of mammary epithelial stem cells, which are interspersed in
the basal myoepithelial layer (9, 69, 72). Specific expression of
Lbh in these cellular targets of canonical Wnt signaling during
normal mammary gland development, as well as the promitogenic
and differentiation-inhibiting effects of Lbh overexpression in
HC11 cells, suggests a potential novel function of LBH in adult
mammary gland tissue homeostasis downstream of Wnt. A pos-
itive relationship between canonical Wnt signaling and Lbh ex-
pression may also have relevance to embryonic heart develop-
ment, where LBH plays a major role (7). This is suggested by a
recent microarray study showing that Lbh induction during car-
diac differentiation of mouse embryonic stem (ES) cells is abol-
ished by inhibition of canonical Wnt signaling (43). Thus, LBH
may act downstream of the canonical Wnt pathway in multiple
aspects of embryonic and adult vertebrate development.
By studying the effects of different Wnt ligands on LBH
expression in tissue culture, we discovered that Wnt7a effi-
ciently blocked Wnt3a-mediated induction of LBH as well as of
the known -catenin target gene DKK1 in 293T cells. More-
over, Wnt7a, which is a tumor suppressor in lung cancer (77),
strongly repressed LBH and DKK1 expression in human
HCC1395 breast cancer cells. To our knowledge, this is the first
evidence that Wnt7a can inhibit canonical Wnt signaling. One
possible mechanism for the observed inhibitory effect could be
that Wnt7a activates the noncanonical planar cell polarity
(PCP) pathway in tissue culture cells (12, 40). However, given
our developmental genetics studies and the fact that Wnt7a
and Wnt5a, which can also activate the PCP pathway (58, 61),
exerted different effects on Wnt3-induced gene expression, we
propose that the inhibitory effect of Wnt7a on canonical Wnt3a
signaling in tissue culture cells could be mediated by a poorly
understood noncanonical pathway involving Lmx1b (37).
The antagonistic relationship between canonical Wnt/-
catenin and noncanonical Wnt7a signaling may have important
implications for dorsoventral limb pattern formation during
embryonic development. It has remained enigmatic how ex-
pression of canonical Wnt target genes gets restricted to ven-
tral limb and AER ectoderm, especially since Wnt3 and its
downstream signaling components are expressed throughout
the limb ectoderm (4, 54, 67). Furthermore, canonical Wnt
signaling activity is detected in some dorsal ectodermal cells as
evident from our TopGal reporter assays. Thus, ectopic ex-
pression of Lbh in distal dorsal limb ectoderm of mouse
mutants lacking Wnt7a pathway activity (Wnt7a/ and
Lmx1b/) together with the repressive effects of Wnt7a on
canonical Wnt signaling in tissue culture cells suggests that
Wnt7a-Lmx1b signaling may be an important repressive mech-
anism that blocks Wnt/-catenin target gene expression, and
consequently ventral differentiation, in dorsal limb ectoderm.
Most importantly, aberrant overexpression of LBH in
MMTV-Wnt1 mammary tumors, as well as in human breast
tumors and cell lines, provides the first indication that somatic
gain of LBH function occurs in cancer. Notably, LBH is spe-
cifically deregulated in ER-negative breast tumors and corre-
lates strongly with the most clinically aggressive basal-like tu-
mor phenotype (66). Elevated expression of LBH mRNA is
observed in approximately half of basal-like tumors but is
present in only 16 to 23% of luminal breast tumors, which have
a good prognosis (66). Since only a few distinct molecular
markers have been identified to date that are uniquely associ-
ated with basal-like breast cancers (47, 59), LBH may prove to
be a valuable diagnostic marker for this difficult-to-treat clin-
ical subtype.
The strong correlation between expression of LBH and ca-
nonical Wnt pathway genes in basal breast tumors, as well as
TOPFlash reporter and inhibition assays in breast tumor cell
lines, furthermore suggests that dysregulation of LBH in breast
cancer is due, at least in part, to aberrant Wnt/-catenin sig-
naling. We detected high Wnt signaling activity in all LBH-
expressing basal breast carcinoma cell lines (HCC1187 and
HCC1395) except for MDA-MB-231 with cell-based TOP-
Flash reporter assays. However, recent short hairpin RNA
(shRNA) knockdown studies of the Wnt coreceptor LRP6
suggest that MDA-MB-231 cells do have some endogenous
Wnt signaling activity (42), which may account for LBH ex-
pression in this cell line. Moreover, this result may suggest that
other, as-yet-unidentified, signaling pathways may also contrib-
ute to LBH overexpression in breast cancer. In further support
of a clinical association of LBH with Wnt/-catenin signaling,
additional meta-analysis showed that LBH overexpression also
correlates with Wnt pathway gene expression in colon cancer
(A. H. Sims, unpublished data), which is primarily driven by
Wnt activating mutations (18). Although deregulation of LBH
in congenital heart disease is associated with increased LBH
gene dosage, aCGH analysis does not suggest that increased
LBH gene copy number is the underlying cause for LBH de-
regulation in basal-like breast cancers. However, we noted that
luminal tumor cell lines frequently displayed a decrease in
LBH copy number, suggesting that a decrease in LBH gene
dosage may play a role in inactivation of LBH in ER-positive
luminal tumors. Genomic instability inherent to tumor cells
may also lead to LBH overexpression in other human cancers,
as karyotypic anomalies involving translocation or triplication
of chromosomal region 2p23, where LBH maps, are frequently
observed in hematopoietic malignancies, testicular cancers,
and neuroblastomas (20, 27, 35, 60). Thus, deregulation of
LBH may be a more general event in human cancer.
In summary, our findings raise the intriguing possibility that
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LBH may act as a downstream effector of canonical Wnt/-
catenin signaling in both normal and neoplastic epithelial de-
velopment, which is under the tight control of antagonistic
noncanonical Wnt7a signaling.
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